Evidence map›Paper›PMID 36448927›Full record

ArticleMolecular pharmaceutics2023

Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections.

Daiqin Chen, Xin Yun, Daiheon Lee, Joseph R DiCostanzo, Oreola Donini, Cecilia M Shikuma, Karen Thompson, Axel T Lehrer, Larissa Shimoda, Jung Soo Suk

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Daiqin ChenCenter for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, United States.
Xin YunDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Daiheon LeeCenter for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, United States.
Joseph R DiCostanzoKaiser Permanente, Honolulu, Hawai'i 96814, United States.
Oreola DoniniSoligenix, Inc., Princeton, New Jersey 08540, United States.
Cecilia M ShikumaDepartment of Medicine, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawai'i 96813, United States.
Karen ThompsonDepartment of Pathology, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawai'i 96813, United States.
Axel T LehrerDepartment of Tropical Medicine, Medical Microbiology & Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawai'i 96813, United States.
Larissa ShimodaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Jung Soo SukCenter for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, United States.ORCID 0000-0002-2437-0001
Johns Hopkins University · USUniversity of Hawaiʻi at Mānoa · USKaiser Permanente · USSoligenix (United States) · US

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI JEFFREY MUMM · 1985 to 2026
$22.1M
Tracking and Evaluation CoreU54GM138062 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI SHIKUMA, CECILIA M. · 2021 to 2025
$15.5M
Na+/H+ exchange in pulmonary hypertensionR01HL073859 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SHIMODA, LARISSA A. · 2003 to 2020
$4.2M
New Inhalation Therapy for COPDR01HL136617 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI NEPTUNE, ENID R, SUK, JUNG SOO · 2017 to 2020
$1.6M
NEI NIH HHS P30 EY001765NHLBI NIH HHS R01 HL073859NHLBI NIH HHS R01 HL136617NIGMS NIH HHS U54 GM138062
6 · The paper itself

Abstract

Vaccine hesitancy and the occurrence of elusive variants necessitate further treatment options for coronavirus disease 2019 (COVID-19). Accumulated evidence indicates that clinically used hypertensive drugs, angiotensin receptor blockers (ARBs), may benefit patients by mitigating disease severity and/or viral propagation. However, current clinical formulations administered orally pose systemic safety concerns and likely require a very high dose to achieve the desired therapeutic window in the lung. To address these limitations, we have developed a nanosuspension formulation of an ARB, entirely based on clinically approved materials, for inhaled treatment of COVID-19. We confirmed

Indexed as

COVID-19Respiratory Tract InfectionsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnimalsRenin-Angiotensin SystemSARS-CoV-2TelmisartanAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsTelmisartanacute respiratory distress syndrome (ARDS)inhalational therapynanosuspensionrenin-angiotensin systemrespiratory infection

Identifiers

PMID36448927
PMCPMC9718101
OpenAlexW4310415967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.